Note: All changes are versus the prior-year period unless otherwise stated
"In 2020, Regeneron delivered double-digit top- and bottom-line growth and significant shareholder value despite the unprecedented circumstances of a global pandemic," remarked chief financial officer Robert Landry.
CEO Leonard Schleifer said that "in 2021, in addition to our ongoing work on COVID-19, we expect further diversified growth driven by continued Eylea momentum, expanded approvals and increased market penetration for Dupixent, and new launches for Libtayo in oncology." He noted that US regulatory action for Libtayo in both non-small-cell lung cancer and basal cell carcinoma is expected "within the next month," with additional readouts "later this year from across our oncology pipeline, including the bispecific platform."
Regeneron said it has initiated a Phase III programme with partner Sanofi to test the anti-IL-33 antibody itepekimab in chronic obstructive pulmonary disease. Separately on Friday, Sanofi disclosed during its earnings call that itepekimab would not be pursued in asthma. Regeneron also said that a Phase III study of REGN5713-5714-5715, a multi-antibody therapy to the Betv1 allergen, recently got under way as a potential treatment for people with birch pollen allergies.
To read more Top Story articles, click here.